A new class of drug for pulmonary arterial hypertension - Can a Rho-Kinase inhibitor break the stagnation in treating it?

Circulation Journal

Volumn 77, Issue 10, 2013, Pages 2477-2478

  Miyagawa, Kazuya ^a   Emoto, Noriaki ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; FASUDIL; MACITENTAN; NITRIC OXIDE; PROSTACYCLIN; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RIOCIGUAT; SELEXIPAG;

BRAIN VASOSPASM; CONTROLLED CLINICAL TRIAL (TOPIC); EDITORIAL; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

EID: 84884615008     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0951     Document Type: Editorial

References (15)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
2. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest 2012; 142: 448-456.
3. Gatfeld J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other en-dothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 2012; 7: e47662, doi:10.1371/journal.pone.0047662.
4. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: An emerging option in pulmonary hypertension therapy. Eur Respir Rev 2009; 18: 35-41.
5. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N, et al. Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40: 874-880.
6. Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol 2011; 7: 657-671.
7. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011; 75: 1801-1810.
8. Connolly MJ, Aaronson PI. Key role of the RhoA/rho kinase system in pulmonary hypertension. Pulm Pharmacol Ther 2011; 24: 1-14.
9. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012; 122: 4306-4313.
10. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-393.
11. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007; 100: 923-929.
12. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, et al. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174-178.
13. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, et al. Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension: A pilot efficacy trial. Circ J 2013; 77: 2619-2625.
14. Grieve AP, Chow SC, Curram J, Dawe S, Harnisch LO, Henig NR, et al. Advancing clinical trial design in pulmonary hypertension. Pulm Circ 2013; 3: 217-225.
15. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galie N, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S97-S107.